Maxwell Biosciences
Maxwell Biosciences is a preclinical stage biotechnology company founded in 2016, focused on developing innovative anti-infective therapeutics using their CLAROMER® platform. Their mission is to create health for the world safely and affordably by harnessing synthetic immune system technology to combat infectious diseases, reverse aging, and provide broad-spectrum biodefense solutions. They utilize advanced peptidomimetic technology to develop stable, low molecular weight compounds that mimic natural antimicrobial peptides, targeting viruses, bacteria, fungi, and biofilms. Their lead drug candidate, MXB-22,510, mimics LL-37 and is designed to be effective against a wide range of pathogens, with human trials planned for 2026.
Industries
Nr. of Employees
small (1-50)
Maxwell Biosciences
Austin, Texas, United States, North America
Patents
Products
Lead peptidomimetic anti-infective candidate (nasal spray program)
A low-molecular-weight peptidomimetic developed for intranasal delivery to inactivate airborne pathogens and disrupt upper-airway biofilms; progressed through preclinical animal studies with regulatory engagement and first-in-human trials planned.
Oral peptidomimetic candidate (early-stage)
An oral small-molecule peptidomimetic program in early development targeting gastrointestinal infectious indications and microbiome imbalance.
Microbiome‑sparing cosmetic ingredient (formulation additive)
A stable small-molecule antimicrobial additive intended for integration into cosmetics and personal care products to reduce microbial contamination while preserving the skin microbiome and formulation stability.
Claromer
A breakthrough class of small, stable, synthetic molecules that mimic part of the human immune system, helping defend skin's surface and cosmetics from unwanted microbial buildup without harming the microbiome's natural balance.
MXB-22,510
Lead drug candidate that accurately mimics LL-37, showing broad-spectrum efficacy against many pathogens with no adverse effect on the human gut microbiome.
Lead peptidomimetic anti-infective candidate (nasal spray program)
A low-molecular-weight peptidomimetic developed for intranasal delivery to inactivate airborne pathogens and disrupt upper-airway biofilms; progressed through preclinical animal studies with regulatory engagement and first-in-human trials planned.
Oral peptidomimetic candidate (early-stage)
An oral small-molecule peptidomimetic program in early development targeting gastrointestinal infectious indications and microbiome imbalance.
Microbiome‑sparing cosmetic ingredient (formulation additive)
A stable small-molecule antimicrobial additive intended for integration into cosmetics and personal care products to reduce microbial contamination while preserving the skin microbiome and formulation stability.
Claromer
A breakthrough class of small, stable, synthetic molecules that mimic part of the human immune system, helping defend skin's surface and cosmetics from unwanted microbial buildup without harming the microbiome's natural balance.
MXB-22,510
Lead drug candidate that accurately mimics LL-37, showing broad-spectrum efficacy against many pathogens with no adverse effect on the human gut microbiome.
Services
Management and execution of preclinical efficacy, safety, PK/PD and IND-enabling studies to support regulatory filings and first-in-human trials.
Collaborative projects with academic and national labs that include high-resolution imaging (EM, tomography) and mechanistic studies of anti-infective candidates.
Licensing and technical support to integrate microbiome-sparing broad-spectrum antimicrobial small molecules into personal care and cosmetic products.
Partnerships and sponsored research with government agencies and academic institutions to support preclinical testing and biodefense-focused development.
Management and execution of preclinical efficacy, safety, PK/PD and IND-enabling studies to support regulatory filings and first-in-human trials.
Collaborative projects with academic and national labs that include high-resolution imaging (EM, tomography) and mechanistic studies of anti-infective candidates.
Licensing and technical support to integrate microbiome-sparing broad-spectrum antimicrobial small molecules into personal care and cosmetic products.
Partnerships and sponsored research with government agencies and academic institutions to support preclinical testing and biodefense-focused development.
Expertise Areas
- Antimicrobial drug discovery
- Peptidomimetic therapeutics
- Preclinical pharmacology and toxicology
- Biofilm therapeutics
Key Technologies
- Peptoid / N-substituted glycine oligomer chemistry
- Peptidomimetic small-molecule synthesis on solid support
- Cryo-electron microscopy
- Soft X-ray tomography